<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01012102</url>
  </required_header>
  <id_info>
    <org_study_id>EMR 200032-001</org_study_id>
    <nct_id>NCT01012102</nct_id>
  </id_info>
  <brief_title>EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>An Open Label, Parallel Group, Randomized Phase I Study of Biological Activity, Safety, Tolerability, and Clinical Activity of Different Dose Levels of EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare 3 doses of EMD 640744 administered by subcutaneous injection in combination with
      Montanide® ISA 51 VG with regard to immunological efficacy.

      The primary target variable is the immune response as assessed by ELISPOT before and until
      week 17 after vaccination with EMD 640744 in Montanide® ISA 51 VG.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare 3 doses of EMD 640744 administered by subcutaneous injection in combination with Montanide® ISA 51 VG with regard to immunological efficacy</measure>
    <time_frame>1-4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of different doses of EMD 640744 in Montanide® ISA 51 VG in terms of laboratory parameters and adverse event profile.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the clinical efficacy in terms of the overall response, progression-free survival time, and survival time.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EMD 640744 30μg and Montanide® ISA 51 VG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EMD 640744 100μg and Montanide® ISA 51 VG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EMD 640744 300μg and Montanide® ISA 51 VG</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EMD 640744</intervention_name>
    <description>EMD 640744 30μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EMD 640744</intervention_name>
    <description>EMD 640744 100μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EMD 640744</intervention_name>
    <description>EMD 640744 300μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Montanide ISA 51 VG</intervention_name>
    <description>Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 30ug)</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Montanide ISA 51 VG</intervention_name>
    <description>Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 100ug)</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Montanide ISA 51 VG</intervention_name>
    <description>Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 300ug)</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects ≥18 years of age

          -  Signed written informed consent

          -  Histologically or cytologically documented metastatic or locally advanced
             survivin-expressing solid tumor for which no established therapy exists

          -  Disease must be measurable by RECIST criteria or evaluable by clinical, radiographic,
             or laboratory criteria established for the given tumor entity

          -  Expressing at least one of the following HLA alleles:HLA-A1,-A2,-A3,-A24, and -B7
             assessed by HLAgenotyping

          -  ECOG performance status of ≤1, estimated life expectancy of at least 3 months

          -  Adequate hematological function defined by WBC ≥3 x 10x9/L, lymphocyte count ≥0.5 x
             10x9/L, hemoglobin ≥10 g/dL, platelet count ≥100 x 10x9/L

          -  Adequate blood coagulation parameters defined as aPTT and INR ≤ 1.5 x ULN

          -  Adequate renal function defined by a serum creatinine ≤2 x ULN

          -  Adequate hepatic function defined by total bilirubin ≤2 x ULN and AST and ALT levels
             ≤2.5 x ULN (in subjects with liver metastases ≤5 x ULN)

          -  Effective contraception for female and male subjects if the risk of conception exists

        Exclusion Criteria:

          -  Treatment in another clinical study within the past 30 days prior to the first
             administration of study treatment

          -  Previous treatment with an investigational anticancer vaccine

          -  Requirement of concurrent treatment with a nonpermitted drug

          -  Active significant autoimmune disease (with the exception of vitiligo)

          -  Receipt of allogeneic stem cell transplantation

          -  Significant acute or chronic infections (e.g. viral hepatitis, HIV)

          -  Primary brain tumors and brain metastases (with the exception of brain metastases that
             are stable after irradiation or surgically resected brain metastases if subjects have
             been asymptomatic for ≥6 months)

          -  Rapidly progressive disease (e.g. tumor lysis syndrome)

          -  Radiotherapy, chemotherapy, surgery (excluding prior diagnostic biopsy), immunotherapy
             or any investigational drug within 30 days before the start of study treatment

          -  Pregnancy or lactation

          -  Active drug or alcohol abuse

          -  Known hypersensitivity to the study treatment or any of its components

          -  Any significant disease that, in the Investigator's opinion, should exclude the
             subject from the study; for questions about this criterion, the Investigator should
             contact the sponsor.

          -  Persisting toxicity related to prior therapy ≥grade 2 National Cancer Institute-Common
             Terminology Criteria For Adverse Events version 3.0

          -  Legal incapacity or limited legal capacity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens-Peter Marschner, MD</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA, Darmstadt</affiliation>
  </overall_official>
  <results_reference>
    <citation>Lennerz V, Gross S, Gallerani E, Sessa C, Mach N, Boehm S, Hess D, von Boehmer L, Knuth A, Ochsenbein AF, Gnad-Vogt U, Zieschang J, Forssmann U, Woelfel T, Kaempgen E. Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunol Immunother. 2014 Apr;63(4):381-94. doi: 10.1007/s00262-013-1516-5. Epub 2014 Feb 2.</citation>
    <PMID>24487961</PMID>
  </results_reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2009</study_first_submitted>
  <study_first_submitted_qc>November 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2009</study_first_posted>
  <last_update_submitted>February 19, 2014</last_update_submitted>
  <last_update_submitted_qc>February 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EMD 640744</keyword>
  <keyword>Montanide</keyword>
  <keyword>Advanced solid tumours</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Freund's Adjuvant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

